Results from a randomized controlled trial published this week in the American Heart Association’s journal Stroke demonstrate that stroke survivors were twice as likely to take anti-blood clot treatment (anticoagulants) when using an artificial intelligence (AI) platform than patients receiving treatment as usual. The AI platform (AiCure, New York, NY) uses software algorithms on smartphones to automatically confirm…